Evidence map›Paper›PMID 32082970›Full record

ReviewActa pharmaceutica Sinica. B2020

Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication.

Chenyang Xiang, Yuxuan Zhang, Weisheng Guo, Xing-Jie Liang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Curcumin coating: a novel solution to mitigate inherent carbon nanotube toxicity.Journal of materials science. Materials in medicine · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Chenyang XiangTranslational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
Yuxuan ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
Weisheng GuoTranslational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
Xing-Jie LiangTranslational Medicine Center, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
State Key Laboratory of Respiratory Disease · CNGuangzhou Medical University · CNNational Center for Nanoscience and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, nanotechnology is revolutionizing the approaches to different fields from manufacture to health. Carbon nanotubes (CNTs) as promising candidates in nanomedicine have great potentials in developing novel entities for central nervous system pathologies, due to their excellent physicochemical properties and ability to interface with neurons and neuronal circuits. However, most of the studies mainly focused on the drug delivery and bioimaging applications of CNTs, while neglect their application prospects as therapeutic drugs themselves. At present, the relevant reviews are not available yet. Herein we summarized the latest advances on the biomedical and therapeutic applications of CNTs

Indexed as

AD, Alzheimer's diseaseALS, amyotrophic lateral sclerosisaSWCNTs, aggregated SWCNTsBBB, blood–brain barrierCarbon nanotubesCNS, central nervous systemCNT-N, nitrogen-doped carbon nanotubesCNTs, carbon nanotubesCpG, oligodeoxynucleotidesDrug deliveryDTPA, diethylentriaminepentaaceticEBs, embryoid bodiesEDC·HCl, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloridef-CNTs, functionalized carbon nanotubesGO, graphene oxideHD, Huntington's diseasehNSCs, human neural stem cellsInherent medicationMCAO, middle cerebral artery occlusionMETH, methamphetamineMPO, myeloperoxidaseMWCNTs, multi-walled carbon nanotubesMWCNTTs, multi-walled nanotube towersND, nanodiamondNervous system diseasesNHS, N-hydroxysuccinimideNR, nanorodNSCs, neural stem cellsPBEC, porcine brain endothelial cellsPCL, polycaprolactonePD, Parkinson's diseasePEG, polyethylene-glycolPET, position emission tomographyPMo11V, tetrabutylammonium salt of phosphovanadomolybdatePOCs, polycyclic organic compoundsPPy/SWCNT, polypyrrole/single-walled carbon nanotubeRES, reticuloendothelial systemsiRNA, small interfering RNASWCNTP, single-walled nanotube paperSWCNTs, single-walled carbon nanotubesTherapeutic drugTLR9, the toll-like receptor-9TMZ, temozolomideToxicity

Identifiers

PMID32082970
PMCPMC7016289
OpenAlexW2986005986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.